


Introduction

Major advances have been made in harnessing natural killer (NK) cells in cancer immunotherapy in recent years. Regulated by their germline-encoded activating and inhibitory receptors, NK cells can recognize and eliminate tumor cells rapidly without prior sensitization. Clinical evidence has shown that donor-derived NK cells pose a low risk of inducing graft-versus-host-disease (GVHD), thus making them ideal candidates for allogeneic transplantation¹. NK cells and T cells share similar killing machineries. Accordingly, NK cells can also be redirected by

chimeric antigen receptors (CARs) against tumor cells. To simplify the manufacturing procedure and facilitate the clinical application of CAR NK cells, here we developed a highly efficient process to generate CAR NK cells under good manufacturing practice (GMP)-compliant conditions in a closed system using the CliniMACS Prodigy® Platform. The process covers the complete procedure of NK cell manufacturing, including cell separation, activation, gene modification, and expansion/cultivation.

Methods and results


1 The CliniMACS Prodigy® LP-3-56-System for NK cell isolation



The CliniMACS Prodigy® LP-3-56 System enables fully automated, two-step isolation of NK cells from fresh leukapheresis samples in a single tubing set (CliniMACS Prodigy® TS 320). The process comprises distinct blocks: i) CD3⁺ cell depletion, which can also be used as a stand-alone process, and ii) CD56⁺ cell enrichment.

The CliniMACS Prodigy® LP-3-56 System resulted in a 3.8 log depletion of CD3⁺ cells (Fig. 1A), and an 87% NK cell recovery on average after CD3⁺ cell depletion (Fig. 1B). Subsequent CD56⁺ cell enrichment resulted in a 4.1 log depletion of CD3⁺ cells (Fig. 1A), and a 41% NK cell recovery on average (Fig. 1B). The resulting NK cell product contained about 2.7×10^8 NK cells (Fig. 1C) with 98% purity on average (Fig. 1D).


2 The natural killer cell engineering (NKCE) process on the CliniMACS Prodigy®



For the generation of genetically engineered NK cells we developed the NKCE process. It consists of two separate steps: i) CD3⁺ cell depletion using the CliniMACS Prodigy® LP-3-56 system and TS 320, and ii) CD56⁺ cell enrichment and manipulation using the


CliniMACS Prodigy® PD-56-engineering system and TS 520. After CD3⁺ cell depletion and CD56⁺ cell enrichment an average NK cell purity of 93% and an average T cell log depletion of 4.3 (n = 7).

3 CAR NK cell generation and expansion using the NKCE process



NK cells, obtained by the separation steps of the NKCE process, were activated on day 0 with IL-2, IL-15, and a cytokine from the IL-1 family. The transduction process using baboon-enveloped lentiviral vector took place on day 2 of the culture. For the expansion phase from day 3 to 14 only IL-2 and IL-15 were added. Cells were cultured in the absence of feeder cells. Figure 3 exemplifies a typical (CAR) NK growth curve resulting in 1.4×10^9 NK cells with a transduction efficiency of 66% (9.5×10^8 CAR NK cells) on day 14.

4 Quality assessment of final CAR NK cell product



The transduction of NK cells in a GMP-compliant system resulted in a stable (day 7 compared to day 14) and high transduction efficiency of 45% at the end of the culture (median; n = 9). On average the expansion resulted in 1.19×10^9 NK cells including 5.7×10^8 CAR NK cells. The culture of transduced NK cells resulted in a cellular product with high NK cell purity (>99%), low CD3⁺ cell content (mean 0.09%), and a good viability with an average of 90% (n = 8).

5 Conclusion

We developed a novel process for automated NK cell purification, transduction, and cultivation in a closed GMP-compliant system. The high level of automation

enables standardized, consistent, and operator-independent genetic engineering of NK cells for future clinical applications.

Reference

1. Leung W. Infusions of Allogeneic Natural Killer Cells as Cancer Therapy. *Clin Cancer Res* 2014;20:3390-3400.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485. In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System. In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. CliniMACS, CliniMACS Prodigy, MACS, PepTivator and the MACS logo are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. Copyright © 2018 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.